Your browser doesn't support javascript.
loading
Non-dystrophic myotonia: 2-year clinical and patient reported outcomes.
Fullam, Timothy R; Chandrashekhar, Swathy; Farmakidis, Constantine; Jawdat, Omar; Pasnoor, Mamatha; Dimachkie, Mazen M; Statland, Jeffrey M.
Afiliação
  • Fullam TR; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Chandrashekhar S; Department of Neurology, Brooke Army Medical Center, JBSA-Fort Sam, Houston, Texas, USA.
  • Farmakidis C; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Jawdat O; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Pasnoor M; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Dimachkie MM; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Statland JM; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Muscle Nerve ; 66(2): 148-158, 2022 08.
Article em En | MEDLINE | ID: mdl-35644941
ABSTRACT
INTRODUCTION/

AIMS:

Consistency of differences between non-dystrophic myotonias over time measured by standardized clinical/patient-reported outcomes is lacking. Evaluation of longitudinal data could establish clinically relevant endpoints for future research.

METHODS:

Data from prospective observational study of 95 definite/clinically suspected non-dystrophic myotonia participants (six sites in the United States, United Kingdom, and Canada) between March 2006 and March 2009 were analyzed. Outcomes included standardized symptom interview/exam, Short Form-36, Individualized Neuromuscular Quality of Life (INQoL), electrophysiological short/prolonged exercise tests, manual muscle testing, quantitative grip strength, modified get-up-and-go test. Patterns were assigned as described by Fournier et al. Comparisons were restricted to confirmed sodium channelopathies (SCN4A, baseline, year 1, year 2 n = 34, 19, 13), chloride channelopathies (CLCN1, n = 32, 26, 18), and myotonic dystrophy type 2 (DM2, n = 9, 6, 2).

RESULTS:

Muscle stiffness was the most frequent symptom over time (54.7%-64.7%). Eyelid myotonia and paradoxical handgrip/eyelid myotonia were more frequent in SCN4A. Grip strength and combined manual muscle testing remained stable. Modified get-up-and-go showed less warm up in SCN4A but remained stable. Median post short exercise decrement was stable, except for SCN4A (baseline to year 2 decrement difference 16.6% [Q1, Q3 9.5, 39.2]). Fournier patterns type 2 (CLCN1) and 1 (SCN4A) were most specific; 40.4% of participants had a change in pattern over time. INQoL showed higher impact for SCN4A and DM2 with scores stable over time.

DISCUSSION:

Symptom frequency and clinical outcome assessments were stable with defined variability in myotonia measures supporting trial designs like cross over or combined n-of-1 as important for rare disorders.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canalopatias / Miotonia / Distrofia Miotônica / Miotonia Congênita Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies Limite: Humans Idioma: En Revista: Muscle Nerve Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canalopatias / Miotonia / Distrofia Miotônica / Miotonia Congênita Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies Limite: Humans Idioma: En Revista: Muscle Nerve Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos